Adc Therapeutics SaADCT
ASignal's systematic analysis rates ADCT as Bearish.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ADCT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current ratio of 3.03x indicates strong short-term liquidity
- Quick ratio of 2.86x supports near-term financial stability
- Positive cash position with $219.11M in total cash
- RSI near 40 suggests potential oversold conditions
- Negative gross, operating, and net margins indicate severe profitability issues
- Forward P/E of -0.64x and negative EV/EBITDA suggest unprofitable operations
- Price below SMA20 and SMA50 indicates ongoing downtrend
- Negative free cash flow of $-68.12M raises sustainability concerns
- No Reddit mentions, indicating low retail investor interest or visibility
See the full verdict on ADCT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ADCT
Most investors never get a second opinion, let alone several. ASignal runs ADCT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.